HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E1908 HRO761 HRO761 is a potent, selective, allosteric inhibitor of Werner syndrome RecQ helicase (WRN). It binds at the interface of the D1 and D2 helicase domains, locking WRN in an inactive conformation, and demonstrates anti-proliferative effects specifically in microsatellite instability (MSI) cancer cells. Jun 10 2024
E4596 GSK-2879552 GSK-2879552 is a selective and potent inhibitor of Lysine-specific demethylase 1 (LSD1, KDM1A), with the potential to treat Small cell lung cancer (SCLC). It induces the expression of putative KDM1A target genes and demonstrates potent, predominantly cytostatic, antiproliferative activity in SCLC cell lines and tumor xenograft models. Jun 07 2024
E4595 SB-743921 SB-743921 (SB-921) is an inhibitor of Kinesin Spindle Protein (KSP), a mitotic protein essential for cell cycle control and motility. It functions by selectively targeting rapidly dividing cells and disrupting spindle formation during cell division, leading to G2/M phase arrest and ultimately causing cell death. It also inhibits proliferation and induces apoptosis in diffuse large B-cell lymphoma (DLBCL) cell lines. Jun 07 2024
S7512 GSK269962A GSK269962A is a potent and selective inhibitor of ROCK with IC50 values of 1.6 nM for ROCK1 and 4 nM for ROCK2. It shows potential as an alternative treatment for overactive bladder (OAB), and also exhibits anti-inflammatory and vasodilatory activities. Jun 06 2024
S9894 Vafidemstat Vafidemstat(ORY-2001) is a potent, selective, brain-penetrant dual inhibitor of lysine-specific histone demethylase (LSD1, KDM1A) and MAO-B, with IC50 values of 105 nM and 58 nM, respectively. It shows potential for treating memory deficits and behavioral alterations in neurodegenerative and psychiatric diseases. Jun 06 2024
E4593 Benzo-15-crown-5 ether Benzo-15-crown-5-ether (B15C5) is employed as a ligand in metal-catalyzed reactions to improve reactivity and selectivity by coordinating with metal cations. Additionally, it serves as a chelating agent for sodium and potassium ions. Jun 06 2024
E1872 Selnoflast Selnoflast(RO-7486967) is a selective and reversible small molecule inhibitor of NLRP3 inflammasome, with the potential to treat moderate to severe active ulcerative colitis. Jun 03 2024
E1625 Elsubrutinib Elsubrutinib(ABBV-105) is a covalent, irreversible, potent, and highly selective inhibitor of Bruton’s Tyrosine Kinase (BTK), with an IC50 of 0.18 μM for BTK catalytic domain. It specifically inhibits BTK dependent cellular functions, including both BCR and FcγR mediated signaling. It also exhibits significant efficacy in pre-clinical mechanistic models of antibody production, as well as in models of rheumatoid arthritis and lupus. Jun 03 2024
E1878 Bromoenol lactone Bromoenol lactone((6E)-Bromoenol lactone) is a selective, irreversible, potent inhibitor of calcium-independent phospholipase A2 (iPLA2β) with an IC50 value of ≈7 μM. It prevents antigen-stimulated exocytosis in mast cells without hindering Ca2+ influx. Jun 02 2024
E1761 AMG PERK 44 AMG PERK 44 is a highly selective and orally active inhibitor of PERK with an IC50 of 6 nM. AMG PERK 44 exhibits 1000-fold and 160-fold selectivity over GCN2 and B-Raf, respectively. Jun 02 2024
E1922 OX04528 OX04528 (compound 68) is a potent and G-protein-biased agonist of G protein-coupled receptor 84 (GPR84). OX04528 inhibits cAMP production with an EC50 value of 0.00598 nM (5.98 pM), respectively. Jun 02 2024
E1907 HADA hydrochloride HADA hydrochloride (HCC-Amino-D-alanine hydrochloride) is a blue fluorescent D-amino acid (FDAA) that labels peptidoglycans in live bacteria without affecting growth and also displays mitochondrial outer membrane permeability. May 28 2024
E1884 HC-258 HC-258 is a covalent acrylamide inhibitor of TEAD that reduces the CTGF, CYR61, AXL, and NF2 transcript levels and inhibits the migration of MDA-MB-231 breast cancer cells. May 27 2024
E1536 (R)-HTS-3 (GLXC-25878) (R)-HTS-3 (GLXC-25878) is a potent, selective, and cell-active inhibitor of lysophosphatidylcholine acyltransferase 3 (LPCAT3) with an IC50 of 0.09 µM, an enzyme critical for synthesizing C20:4-containing phospholipids. It reduces arachidonic acid-d8 incorporation into phospholipids and mitigates RSL3-induced ferroptosis in HT-1080 and 786-O cancer cells. May 27 2024
E1264 VIT-2763 VIT-2763 is an oral small-molecule inhibitor of ferroportin. It displaces TMR-hepcidin from ferroportin with an IC50 of 24 nM. It also ameliorates anemia, enhances erythropoiesis, and reduces organ iron loading in the Hbbth3/+ β-thalassemia intermedia disease model. May 23 2024
E1800 Oxythiamine chloride hydrochloride Oxythiamine chloride hydrochloride(Hydroxythiamine chloride hydrochloride) is a salt form of Oxythiamine. It is an inhibitor of transketolase, the enzyme that controls the nonoxidative branch of the pentose phosphate pathway. It also suppresses tumor cell proliferation and promotes apoptosis. May 23 2024
E1385 Bexotegrast Bexotegrast(PLN-74809) is potent dual selective inhibitor of αvβ6 and αvβ1 integrins with Kd of 5.7 nM and 3.4 nM, respectively. It has antifibrogenic effects, blocks multiple TGF-β activation pathways in the fibrotic lung, and is useful for researching fibrosis, including idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP). May 21 2024
E1607 RK-701 RK-701 is a highly selective, potent, and low-toxicity inhibitor of histone methyltransferases G9a and GLP1 with IC50 values of 23-27 nM and 53 nM. RK-701 treatment induces fetal globin expression in human erythroid cells and in mice and plays an essential role in γ-globin induction. RK-701 is used in the research of sickle cell disease. May 19 2024
E1632 VU0463271 VU0463271 is a selective and potent antagonist of neuronal-specific potassium-chloride cotransporter 2 KCC2, with an IC50 of 61 nM. VU0463271 demonstrates over 100-fold selectivity compared to the closely related Na-K-2Cl cotransporter 1 (NKCC1). May 16 2024
E1340 Glesatinib Glesatinib(MGCD265) is an orally bioavailable potent dual inhibitor of c-MET and SMO. Glesatinib counteracts P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC). May 16 2024